Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03489239 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Entecavir to TAF Switch

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 25, 2020 (before its estimated August 15, 2020 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: May 15, 2020 to Aug 15, 2020
    • Study completion date: Aug 16, 2020 to Sep 16, 2020
    v6
  2. Primary completion date: Jan 15, 2020 to May 15, 2020
    • Study completion date: Apr 16, 2020 to Aug 16, 2020
    v5
  3. Primary completion date: Jul 15, 2019 to Jan 15, 2020
    • Study completion date: Nov 16, 2019 to Apr 16, 2020
    v4
  4. Primary completion date: Nov 15, 2018 to Jul 15, 2019
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 54 to confirmed 27
    • Site details revised
    v3
  5. Primary completion date: Jul 31, 2018 to Nov 15, 2018v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
Trial Details
NCT Number NCT03489239
Lead Sponsor Thomas Jefferson University
Collaborators: Gilead Sciences
Conditions
(from sponsor)		 Hepatitis B
Related terms Hepatitis B
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov